Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Repligen

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA

In the study, there were improvements in motor function as well as a slowing of neurodegeneration

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

- PMLiVE

Biogen agrees $850m felzartamab rights deal with TJ Biopharma

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

- PMLiVE

Astellas’ application to EMA validated for treatment of muscle-invasive bladder cancer

Bladder cancer affects over 224,000 people annually in Europe, with over 30% of cases being muscle-invasive bladder cancer

- PMLiVE

Biogen to acquire Apellis in $5.6bn deal

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

Scotland becomes first part of UK to screen all newborn babies for SMA

The screening is part of a two-year evaluation funded by the Scottish government and Novartis

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links